2017

1. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

   The Lancet Respiratory Medicine, Vol. 5, Núm. 5, pp. 435-444

2. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer

   Journal of Clinical Oncology, Vol. 35, Núm. 1, pp. 40-47